Skip to main content

Table 2 PK parameters for each patient

From: Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy

Patient Cmax(μg/mL) Cmin(μg/mL) VD (L/kg) Ke (h–1) CL (L/h) t1/2(h) AUC [0-inf] Dose in mg/kg
1 283.97 13.29 0.26 0.53 7.45 1.31 398.78 54.05
2 200.56 16.87 0.35 0.44 8.70 1.59 419.14 52.63
4 337.21 6.36 0.22 0.69 8.15 1.01 232.15 70.18
5 211.53 18.76 0.35 0.43 8.19 1.60 446.61 46.51
6 153.13 18.74 0.61 0.36 9.30 1.95 311.08 85.11
7 97.37 3.88 0.52 0.57 23.54 1.21 163.28 63.49
8 94.10 2.22 0.65 0.64 27.25 1.08 115.12 58.82
10 465.78 13.64 0.15 0.57 4.93 1.21 607.15 86.96
11 162.34 5.18 0.42 0.53 13.13 1.30 317.32 66.67
12 179.52 37.65 0.45 0.26 5.84 2.65 418.48 60.61
13 318.81 28.34 0.26 0.44 5.48 1.59 667.45 62.50
14 319.55 19.07 0.30 0.50 6.20 1.40 477.15 78.43
15 513.74 4.52 0.10 0.82 6.38 0.85 678.99 86.96
16 1133 0.47 0.08 1.25 4.42 0.55 827.16 66.67
Mean 319.33 13.50 0.34 0.57 9.93 1.38 434.28 67.11
σ(n-1) 266.08 10.71 0.18 0.24 6.95 0.51 205.17 13.01
  1. Mentioned on page 6.